STC 1020
Alternative Names: STC-1020Latest Information Update: 29 Jan 2026
At a glance
- Originator Brenus Pharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Tumour cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer